Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple ...

Both ibuprofen and naproxen potently inhibit hTAS1R2–TAS1R3 receptors that sense sweetness in a dose-dependent manner. The ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

Artificial sweeteners' effects on the gut microbiome are under scrutiny, with evidence suggesting potential risks to ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

By targeting the fundamental issue behind slow metabolism, Mitolyn provides a scientifically backed, sustainable approach to weight management. It is particularly beneficial for individuals who have ...

After reviewing the science, customer testimonials, and expert opinions, the verdict is clear: Prime Biome isn't just another probiotic-it's an advanced formula designed to optimize gut health, ...